Generics giant takes on top-seller

Arrotex will represent Amgen's osteoporosis treatment Prolia under a new partnership that aims to "broaden opportunities" for one of Australia's highest reimbursed drugs.

Prolia contains the active denosumab, which Amgen also markets under the brand name Xgeva and is listed on the PBS for giant cell tumour of bone and bone metastases due to breast cancer or castration-resistant prostate.

Combined, the drugs earned over $286 million in pre-rebate PBS benefits in 2023, however, Prolia contributed $258,455,053 to that figure with both brands facing a looming patent cliff.